国产午夜福利片1000无码丨人妻国产成人久久av免费高清丨午夜做受视频试看6次丨日韩av不卡一区在线免费观看丨在线观看精品三级欧美

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Campylobacter jejuni subsp. jejuni serotype O:23/36 50S ribosomal protein L22 (rplV) CSB-YP380349CWF
CSB-EP380349CWF
CSB-BP380349CWF
CSB-MP380349CWF
CSB-EP380349CWF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:23/36 3-isopropylmalate dehydratase large subunit (leuC) CSB-YP380350CWF
CSB-EP380350CWF
CSB-BP380350CWF
CSB-MP380350CWF
CSB-EP380350CWF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:23/36 NADPH-dependent 7-cyano-7-deazaguanine reductase (queF) CSB-YP380351CWF
CSB-EP380351CWF
CSB-BP380351CWF
CSB-MP380351CWF
CSB-EP380351CWF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. C4-dicarboxylate transport protein (dctA), partial CSB-YP380352AUC
CSB-EP380352AUC
CSB-BP380352AUC
CSB-MP380352AUC
CSB-EP380352AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. Acetaldehyde dehydrogenase (Ajs_0223) CSB-YP380353AUC
CSB-EP380353AUC
CSB-BP380353AUC
CSB-MP380353AUC
CSB-EP380353AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. 50S ribosomal protein L4 (rplD) CSB-YP380354AUC
CSB-EP380354AUC
CSB-BP380354AUC
CSB-MP380354AUC
CSB-EP380354AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. 50S ribosomal protein L16 (rplP) CSB-YP380355AUC
CSB-EP380355AUC
CSB-BP380355AUC
CSB-MP380355AUC
CSB-EP380355AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. 30S ribosomal protein S17 (rpsQ) CSB-YP380356AUC
CSB-EP380356AUC
CSB-BP380356AUC
CSB-MP380356AUC
CSB-EP380356AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. Carboxylate-amine ligase Ajs_0357 (Ajs_0357) CSB-YP380357AUC
CSB-EP380357AUC
CSB-BP380357AUC
CSB-MP380357AUC
CSB-EP380357AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. 4-hydroxybenzoate octaprenyltransferase (ubiA), partial CSB-YP380358AUC
CSB-EP380358AUC
CSB-BP380358AUC
CSB-MP380358AUC
CSB-EP380358AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. 50S ribosomal protein L5 (rplE) CSB-YP380359AUC
CSB-EP380359AUC
CSB-BP380359AUC
CSB-MP380359AUC
CSB-EP380359AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. 50S ribosomal protein L18 (rplR) CSB-YP380360AUC
CSB-EP380360AUC
CSB-BP380360AUC
CSB-MP380360AUC
CSB-EP380360AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. 50S ribosomal protein L30 (rpmD) CSB-YP380361AUC
CSB-EP380361AUC
CSB-BP380361AUC
CSB-MP380361AUC
CSB-EP380361AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. DNA-directed RNA polymerase subunit alpha (rpoA) CSB-YP380362AUC
CSB-EP380362AUC
CSB-BP380362AUC
CSB-MP380362AUC
CSB-EP380362AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. Multifunctional CCA protein (cca) CSB-YP380363AUC
CSB-EP380363AUC
CSB-BP380363AUC
CSB-MP380363AUC
CSB-EP380363AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. PKHD-type hydroxylase Ajs_0512 (Ajs_0512) CSB-YP380364AUC
CSB-EP380364AUC
CSB-BP380364AUC
CSB-MP380364AUC
CSB-EP380364AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. Type III pantothenate kinase (coaX) CSB-YP380365AUC
CSB-EP380365AUC
CSB-BP380365AUC
CSB-MP380365AUC
CSB-EP380365AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. Bifunctional protein GlmU (glmU) CSB-YP380366AUC
CSB-EP380366AUC
CSB-BP380366AUC
CSB-MP380366AUC
CSB-EP380366AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. UPF0391 membrane protein Ajs_0703 (Ajs_0703), partial CSB-YP380367AUC1
CSB-EP380367AUC1
CSB-BP380367AUC1
CSB-MP380367AUC1
CSB-EP380367AUC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Acidovorax sp. 1- (5-phosphoribosyl)-5-[ (5-phosphoribosylamino)methylideneamino] imidazole-4-carboxamide isomerase CSB-YP380368AUC
CSB-EP380368AUC
CSB-BP380368AUC
CSB-MP380368AUC
CSB-EP380368AUC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.jhhuazhong.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>